Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...

试验显示，REC-4881（每日一次4毫克）在12周治疗后实现了息肉总负担中位数减少43%，其中75%的可评估患者显示减少。值得注意的是，82%的可评估患者在停止治疗12周后仍保持持久减少，此时观察到基线中位数减少53%。

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Recursion使用人工智能驱动的模型来识别和设计新的疗法，并将这些模型提供给其他制药商，包括罗氏和拜耳。总部位于犹他州盐湖城的Recursion将利用其超过23,000 tb的生物和化学数据集，在英伟达的云平台上训练其人工智能模型。

Recursion Pharmaceuticals ( RXRX +1.91%) was in the headlines on Monday, and for the right reason. One of the biotech company ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) 股价周一上涨7%，此前该公司实验性药物REC-4881在家族性腺瘤性息肉病 (FAP)的2期临床试验中取得积极结果。FAP是一种罕见的遗传疾病，目前尚无获批疗法。

Few would place Recursion Pharmaceuticals ( RXRX +8.44%), a little-known biotech company, in the same league as these tech giants when it comes to AI stocks. But could the small drugmaker actually ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...